SEARCH

SEARCH BY CITATION

References

  • 1
    Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: HollingerBF, LemonSM, MargolisHS, eds. Viral hepatitis and liver disease. Baltimore : Williams & Wilkins, 1991:1420.
  • 2
    Tilzey AJ, Banatvala JE. Hepatitis A: changing prevalence and possible vaccines. BMJ 1991;302:15521553.
  • 3
    Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis 1986;8:548557.
  • 4
    Tabor E. Clinical presentation of hepatitis A. In: GeretyRJ, ed. Hepatitis A. Orlando : Academic Press, 1984:4753.
  • 5
    Centers for Disease Control and Prevention. Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40:4850.
  • 6
    André FE, Hepburn A, D'Hondt E. Inactivated candidate vaccines for hepatitis A. In: MelnickJC, ed. Progress in medical virology. Vol. 37. Basel : Karger, 1990:7295.
  • 7
    Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453457.
  • 8
    Loutan L, Bovier P, Althans B, Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1994;343:322324.
  • 9
    Anonymous. Hepatitis A: a vaccine at last. Lancet 1992;339:11981199.
  • 10
    André FE, D'Hondt ED, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992;10(Suppl):160168.
  • 11
    Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:11341138.
  • 12
    Purcell RH, D'Hondt E, Bradbury R, et al. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 1992;10(Suppl):148151.
  • 13
    Steffen R, Kane MA, Shapiro CN, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994;272:885889.
  • 14
    van Damme P, Cramm M, van Gompel A, et al. Analysis of travellers profile in Belgium. Paris: Proceedings of the Third Conference on International Travel Medicine, April 2629, 1993:Abstract No. 267.
  • 15
    van Damme P, Thoelen S, Van der Auwera JC, et al. Health care workers and hepatitis A. In: HagbergM, HoffmanF, StösselU, WestlanderG, eds. Occupational health for health care workers. Freiburg , Stuttgart : Ecomed-Verlag, 1993:133137.
  • 16
    Doebbeling BN, Li N, Wenzel RP. An outbreak of hepatitis among health care workers: risk factors for transmission. Am J Public Health 1993;83:16791684.
  • 17
    Delem A. Comparison of modified HAVAB and Elisa for detection of vaccine-induced anti-HAV response. Biologicals 1992;20:289291.
  • 18
    Ambrosch F, Wiedermann G, André F, et al. Comparison of HAV antibodies induced by vaccination, passive immunization, and natural infection. In: HolingerFB, LemonSM, MargolisHS, eds. Viral hepatitis and liver disease. Baltimore : Williams & Wilkins, 1991:98100.
  • 19
    Binn LN, MacArthy PO, Marchwicki RH, et al. Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine. Vaccine 1992;10(Suppl):102105.
  • 20
    Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983;148:10331039.
  • 21
    Tilzey AJ, Palmer SJ, Barro S, et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992;304:12721276.
  • 22
    Kallinowski B, Gmelin K, Kommerell B, et al. Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine — a randomized multicentre study with three consecutive vaccine lots. Vaccine 1992;10:500501.
  • 23
    van Damme P, Mathei C, Thoelen S, et al. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994;44:435441.
  • 24
    Davidson M, Krugman S, Sandman LA. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. Vaccine 1992;10(Suppl):119120.
  • 25
    Tilzey AJ, Palmer SJ, Barrow S, et al. Effect of hepatitis A vaccination schedules on immune response. Vaccine 1992;10(Suppl):121123.
  • 26
    Wiedermann G, Ambrosch F, André FE, et al. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992;10(Suppl):129131.
  • 27
    Thoelen S, van Damme P, Cramm M, et al. The safety, reactogenicity and longterm immunogenicity of two lots of an inactivated hepatitis A vaccine. In: HagbergM, HoffmanF, StösselU, WestlanderG, eds. Occupational health for health care workers. Freiburg , Stuttgart : Ecomed-Verlag, 1993:156160.
  • 28
    Westblom TU, Gudipati S, de Rousse C, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 1994;169:9961001.
  • 29
    Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units. Efficacy and subtype cross-protection. N Engl J Med 1982;307:14811489.
  • 30
    Hollinger BF. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989;87(3A):3640.
  • 31
    Hollinger BF, Troisi C, Heilberg D, et al. Response to a hepatitis B polypeptide vaccine in micelle form in a young adult population. J Med Virol 1986;19:229235.
  • 32
    Denis F, Mounier M, Hessel L, et al. Hepatitis-B vaccination in the elderly. J Infect Dis 1984;149:1019.
  • 33
    Ljunggren K, Löfgren B, Nordenfelt E. Varying antibody response in hospital staff vaccinated against hepatitis B. Scand J Infect Dis 1988;20:485488.
  • 34
    Briem H, Wynen J, Safary A. Immunogenicity and reactogenicity of a hepatitis A virus (HAV) vaccine administered as a single dose with a booster at 6 months. Tokyo : International Symposium on Viral Hepatitis and Liver Disease, May 1014, 1993:110(Abstract No. 48).
  • 35
    Just M, Gremmelmaier D, Berger R, et al. Safety and immunogenicity of dose of inactivated hepatitis A vaccine in healthy adults. Tokyo : International Symposium on Viral Hepatitis and Liver Disease, May 1014, 1993:105 (Abstract No. 29).
  • 36
    André FE. Development of a vaccine against hepatitis A. In: HollingerBF, LemonSM, MargolisHS, eds. Viral hepatitis and liver disease. Baltimore : Williams & Wilkins, 1991:8588.
  • 37
    van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and longterm antibody persistence. J Med Virol 1994;44:446451.
  • 38
    Beller M, Krause D. Experience with Havrix in an outbreak setting. Prague : Sixth International Congress for Infectious Diseases, 1994:282 (Abstract No. 878).